Mineralocorticoid receptor antagonists for heart failure

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 18, 2011, Pages 2801-2815

  Richards, Arthur Mark ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Aldosterone; Eplerenone; Heart failure; Mineralocorticoid receptor antagonists; Mineralocorticoid receptors; Spironolactone

Indexed keywords

EPLERENONE; MINERALOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR ANTAGONIST; PLACEBO; RECEPTOR BLOCKING AGENT; SPIRONOLACTONE; UNCLASSIFIED DRUG;

DRUG INDICATION; DRUG USE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PATIENT SELECTION; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 81855183776     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.631524     Document Type: Review

References (108)

1. Crabbe J. Stimulation of active sodium transport by the isolated toad bladder with aldosterone in vitro. J Clin Invest 1961;40:2103-10
2. Hunt SA, Abraham WT, Chin MH, et al. American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J AM Coll Cardiol 2009;53:e1-e90
3. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009;30:469-77
4. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
5. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy Survival Study Investigators. Eplerenone, a selective mMRblocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21
6. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21
7. Davis JO, Carpenter CC, Ayers CR, et al. Evidence for a secretion of an aldosterone stimulating hormone from the kidney. J Clin Invest 1961;40:684-96
8. Davis JO, Hartroft PM, Tins DO, et al. The role of the renin angiotensin system in the control of aldosterone secretion. J Clin Invest 1962;41:378-89
9. Quinn SJ, Williams GH. Regulation of Aldersterone Secretion. Annu Rev Physiol 1988;50:400-26
10. Spat A, Hunyady L. Control of aldosterone secretion in cellular signaling pathways. Physiol Rev 2004;84:489-539
11. Funder JW. Aldosterone and mineralocorticoid receptors in the cardiovascular system. Prog Cardiovasc Dis 2010;52:393-400
12. Okubo S, Niimura F, Nishimura H, et al. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997;99:855-60
13. Conn J. Primary aldosteronism: a new clinical syndrome. J Lab Clin Med 1955;45:3-17
14. Stowasser M, Gordon RD, Gunosekera TG, et al. High rate of detection of primary aldosteronism, including surgically treatable forms, after -non-selective' screening of hypertensive patients. J Hypertens 2003;21:2149-57
15. Nishizaka MK, Zaman MA, Green SA, et al. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004;109:2857-61
16. Levy D, Rocha R, Funder JW. Distinguishing the anti-hypertensive and electrolyte effects of epleronone. J Clin Endocrinol Metab 2004;89:2736-40
17. Funder JW. How do central mineralocorticoid receptors modulate blood pressure? Am J Physiol 2005;288:R356-7
18. Jazayeri A, Meyer WJ. Mineralocorticoid-induced increase in beta-adrenergic receptors of cultured rat arterial smooth muscle cells. J Steroid Biochem 1989;33:987-91
19. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin 2 receptors in the rat. Can J Physiol Pharmacol 1985;63:1522-7
20. Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of hypertension. Hypertension 1993;21:929-33
21. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med 1992;120:893-901
22. Funder JW. Steroids, hypertension and cardiac fibrosis. Blood Press 1995;4:39-42
23. Rocha R, Stier CT. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001;12:308-14
24. Skott O, Uhrenholt TR, Schjerning J, et al. Rapid actions of aldosterone in vascular health and disease-friend or foe? Pharmacol Ther 2006;111:495-507
25. Schmidt BM, Oehmer S, Delles C, et al. Rapid non-genomic effects of aldosterone on human forearm vasculature. Hypertension 2003;42:156-60
26. Romagni P, Rossi F, Guerrini L, et al. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003;166:345-9
27. Gunaruwan P, Schmitt M, Taylor J, et al. Lack of rapid aldosterone effects on forearm resistance vasculature in health. J Renin Angiotensin Aldosterone Syst 2002;3:123-5
28. Schmidt BM, Montealegre A, Janson CP, et al. Short-term cardiovascular effects in healthy male volunteers. J Clin Endocrinol Metab 1999;84:3528-33
29. Wehling M, Specs CH, Win N, et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998;833:517-22
30. Davies JL, Band M, Morris A, et al. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004;47:1687-94
31. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensinI/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7
32. Epstein M, Alexander JC, Roniker B. Eplerenone, a new selective aldosterone receptor antagonist (SARA): efficacy in patients with mild to moderate hypertension. J Am Soc Nephrol 1998;9:A1640
33. Funder JW, Pearce P, Smith R, et al. Mineralocorticoid action: target-tissue specificity is enzyme, not receptor, mediated. Science 1988;242:583-5
34. Edwards CR, Stewart PM, Burt D, et al. Localisation of 11 beta-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 1988;2:986-9
35. Funder JW, Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 1996;137:5264-8
36. Brilla CG, Pick R, Tan LB, et al. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-64
37. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circ Res 1991;83:1849-65
38. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-75
39. Milliez P, Girerd X, Plouin P-F, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J AmColl Cardiol 2005;45:1243-8
40. Stowasser M, Sharman J, Leano R, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005;90:5070-6
41. Weber KT. From inflammation to fibrosis: a stiff stretch of highway. Hypertension 2004;43:716-19
42. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008;51:161-7
43. Kai H, Kuwahara E, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 2005;28:483-90
44. Nicoletti A, Heudes D, Mandet C, et al. Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats. Cardiovasc Res 1996;32:1096-107
45. Lim JY, Park S, Hwang HY, et al. TGF-beta 1 induces cardiac hypertrohic responses via PKC-dependent ATF2-activation. J Mol Cell Cardiol 2005;39:627-36
46. Yokoyama T, Nakano M, Bednarczyk JL, et al. Tumour necrosis factor alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997;95:1247-52
47. Chen M, Lam A, Abraham JA, et al. CTTGF expression is induced by TGF-beta in in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000;32:1805-19
48. Mehta PK, Griendling KK. Angiotensin II cell signalling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-97
49. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al. Angiotensin II activates nuclear transcription factor kappa B through AT1 and AT2 in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000;86:1266-72
50. Nakagami H, Takemoto M, Liao JK. NADPH-oxidase derived superoxide anion mediates angiotensin II -induced cardiac hypertrophy. J Mol Cell Cardiol 2003;35:851-9
51. Fiebeler A, Scmidt F, Muller DN, et al. Mineralocorticoid receptor affects AP-1 and nuclear factor kappa B activation in angiotensin II-induced cardiac injury. Hypertension 2001;37:787-93
52. Ward MR, Kanellakis P, Ramsey D, et al. Eplerenone suppresses constrictive remodelling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 2001;104:467-72
53. Mihailidou AS, Loan Le TY, Mardini M, et al. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009;54:1306-12
54. Mihailidou AS, Mardini M, Fraser T, et al. Agonist/antagonist activity of cortisol in cardiomyocyte mineralo-corticoid receptors is determined by redox state. 30th Annual Meeting of the International Aldosterone Conference; June 14 - 15 2004; New Orleans, LA
55. Taves MD, Gomez-Sanchez CE, Soma KK. Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation and function. Am J Physiol Endocrinol Metab 2011;301:E11-24
56. Yamamoto N, Yasue H, Mizuno Y, et al. Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 2002;39:958-62
57. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-7
58. Tsutamoto T, Wada A, Maeda K, et al. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive cardiac failure. J Am Coll Cardiol 2000;36:383-44
59. Struthers DA. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004;6:539-45
60. Borghi C, Boschi S, Ambrosioni E, et al. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993;33:40-5
61. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999;100:1056-64
62. MacFadyen RJ, Lee AF, Morton JJ, et al. How often are angiotensin II andaldosterone concentrations raised during chronic ACE inhibitor treatment in heart failure? Heart 1999;82:57-61
63. Swedberg K, Eneroth P, Kjekshus J, et al. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (followup of the CONSENSUS trial).Am J Cardiol 1990;66:40D-4D
64. Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohormonal activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998;10:1552-63
65. Guder G, Bauersachs J, Frantz S, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 2007;115:1754-61
66. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol doi:10.1016/j. mce.2011.06.025.
67. Agostini P, Magini A, Andreini D, et al. Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J 2005;26:159-64
68. Akbulut M, Ozbay Y, IlKay E, et al. Effects of sprironolactone and metoprolol on QT dispersion in heart failure. Jpn Heart J 2003;44:681-92
69. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65
70. Berry C, Murphy N, De Vito G, et al. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail 2007;9:429-34
71. Boccanelli A, Cacciatore G, Mureddu GF, et al. Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure).J Cardiovasc Med (Hagerstown) 2007;8:683-91
72. Chan AKY, Sanderson JE, Wang T, et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol 2007;50:591-6
73. Cicoira M, Zanolla L, Rossi A, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol 2002;40:304-10
74. Di Pasquale P, Cannizzaro S, Scalzo S, et al. Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction. Am Heart J 2005;150:919
75. Gao X, Peng L, Adhikari CM, et al. Spironolactone reduced arrhythmia and maintained magnesium homeostatis in patients with congestive heart failure. J Card Fail 2007;13:170-7
76. Modena MG, Aveta P, Menozzi A, et al. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001;141:41-6
77. Mottram PM, Haluska B, Leano R, et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 2004;110:558-65
78. Orea-Tojeda A, Colin-Ramirez E, Castillo-Martinez L, et al. Aldosterone receptor antagonists induce favourable cardiac remodeling in diastolic heart failure patients. Rev Invest Clin 2007;59:103-7
79. Pitt B, Roniker B. Eplerenone, a novel selective aldosterone receptor antagonist (SARA): dose finding study in patients with heart failure. J Am Coll Cardiol 1999;15:188A
80. Rodriguez JA, Godoy I, Castro P, et al. Effects of ramipril and spironolactone on ventricular remodelling after acute myocardial infarction: randomized and double-blind study [Spanish]. Rev Med Chil 1997;125:643-52
81. Study 402. Inspra Drug Approval Package. Food and Drug Administration 2004 September 9. Available from: http://www.fda.gov/cder/foi/nda/2003/ 21-437s002-Inspra.htm [Accessed 17 August 2007]
82. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodelling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-33
83. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study[RALES]).Am J Cardiol 1996;78:902-7
84. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES).Circulation 2000;102:2700-6
85. Iraqi W, Rossignol P, Angioi M, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2009;119:2471-9
86. Weir RAP, Mark PB, Petrie CJ, et al. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am Heart J 2009;157:1088-96
87. Daniel KR, Wells G, Stewart K, et al. Effect of aldosterone antagonism on exercise tolerance, doppler diastolic function, and quality of life in older women with diastolic heart failure. Congest Heart Fail 2009;15:68-74
88. Treatment of preserved cardiac function heart failure with an Aldosterone antagonist trial (TOPCAT).Funded by the National Heart, Lung & Blood Institute, Clinical Trials gov NCT00094302
89. Edelmann F, Schmidt AG, Gelbrich G, et al. Rationale and design of the -aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function in patients with symptomaticdiastolic heart failure (Aldo-DHF).Eur J Heart Fail 2010;12:874-82
90. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).J Am Coll Cardiol 2005;46:1116-43.published correction appears in J Am Coll Cardiol. 2006;47 (7):1502-3
91. Hunt SA, Abraham WT, Chin MH, et al. America College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society. ACC/ AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154-235.published correction appears in Circulation 2006;113:e684-5
92. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 2003;41(2):211-14
93. Tamirisa DP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004;148(6):971-8
94. Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004;10:297-303
95. Shah KB, Rao K, Sawyer R, et al. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005;46:845-9
96. Raebel MA, McClure DL, Chan KA, et al. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia? Ann Pharmacother 2007;41:193-200
97. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51
98. Masoudi FA, Gross CP, Wang Y, et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States. Circulation 2005;112:39-47
99. Albert NM, Yancy CW, Liang L, et al. Use of Aldosterone Antagonists. JAMA 2009;302:1658-65
100. Fonarow GC, Yancy CW, Albert NM, et al. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE-HF. Circ Heart Fail 2008;1:98-106
101. Niemenim MS, Brutsaert D, Dickstein K, et al. EuroHeart Survey Investigators, Heart Failure Association European Society of Cardiology, EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725-36
102. Matra M, Cas LD, Massie BM. Treatment of heart failure in the elderly: never say its too late. Eur Heart J 2009;30:391-3
103. Flather MD, Yusuf F, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-81
104. Cleland JG, Tendera M, Adamus J, et al. PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-45
105. Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction. The CHARM-Preserved trial. Lancet 2003;36:777-81
106. Massie BM, Carson PE, McMurray JJ, et al. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359:2456-67
107. Dulin BR, Haas SJ, Abraham WT, et al. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-anlysis of >12,000 patients in large-scale clinical trials. Am J Cardiol 2005;95:896-8
108. Flather MD, Shibata MC, Coats AJ, et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).Eur Heart J 2005;26:215-25